Open AccessThe prognostic and predictive significance of plasma type 1 plasminogen activator inhibitor and endoglin in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
Author(s) -
Öznur Bal,
Ahmet Şiyar Ekinci,
Mutlu Doğan,
Çiğdem Atay,
Ayşe Demirci,
Berna Öksüzoğlu,
Selim Kılıç
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1253_16
Subject(s) - bevacizumab , medicine , colorectal cancer , plasminogen activator , gastroenterology , chemotherapy , plasminogen activator inhibitor 1 , endoglin , oncology , cancer , stem cell , biology , cd34 , genetics
This study aims to evaluate the prognostic and predictive value of plasma plasminogen activator inhibitor-1 (PAI-1) and endoglin in metastatic colorectal cancer (mCRC) patients receiving chemotherapy with bevacizumab.